文献速递糖尿病肥胖与代谢综合征

N末端B型利钠肽原与糖尿病及代谢综合征风险

N-terminal Pro-B-Type Natriuretic Peptide and Risk for Diabetes Mellitus and Metabolic Syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

在REGARDS队列2899名参与者中,基线NT-proBNP与随访新发糖尿病、代谢综合征及其组分相关;NT-proBNP与糖尿病风险呈负相关(校正OR每SD对数升高0.80,95%CI 0.69-0.93),与代谢综合征仅最高vs最低四分位负相关(校正OR 0.59,95%CI 0.37-0.92),与血糖异常组分负相关(校正OR 0.65,95%CI 0.53-0.79),与其他组分无关。

要点

  • NT-proBNP每升高1个SD(对数尺度),新发糖尿病风险校正OR为0.80(95%CI 0.69-0.93)。
  • NT-proBNP最高vs最低四分位与新发代谢综合征校正OR为0.59(95%CI 0.37-0.92),线性关联未达统计学显著。
  • NT-proBNP每升高1个SD(对数尺度)与新发血糖异常校正OR为0.65(95%CI 0.53-0.79)。

核心结论

  • NT-proBNP与新发糖尿病、代谢综合征及代谢综合征的血糖异常组分呈负相关。
  • B型利钠肽的代谢意义似乎对血糖稳态有重要作用。

研究设计与样本

  • 在REGARDS研究中,纳入2899名有基线(2003-2007年)和随访(2013-2016年)检查及基线NT-proBNP测量的参与者。
  • 采用逻辑回归模型分析新发代谢综合征、代谢综合征组分和糖尿病,协变量包括人口学、危险因素和实验室因素。
  • 新发糖尿病定义为随访时空腹血糖≥126 mg/dL、随机血糖≥200 mg/dL或使用胰岛素或降糖药物而基线无此情况。
  • 新发代谢综合征定义为随访时符合≥3项协调标准而基线<3项。

主要发现

  • 平均随访9.4年期间,310名参与者(2364名at risk)发生糖尿病,361名参与者(2059名at risk)发生代谢综合征。
  • NT-proBNP与新发糖尿病风险呈负相关(完全校正OR每SD对数NT-proBNP升高0.80,95%CI 0.69-0.93)。
  • NT-proBNP仅最高vs最低四分位与新发代谢综合征呈负相关(完全校正OR 0.59,95%CI 0.37-0.92),线性关联未达统计学显著。
  • NT-proBNP在所有模型中与新发血糖异常呈负相关(完全校正OR每SD对数NT-proBNP 0.65,95%CI 0.53-0.79),但与其他代谢综合征组分无关。
  • 未观察到性别、种族、年龄或体重指数的效应修饰。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Natriuretic peptide concentrations are inversely associated with risk of diabetes mellitus and may be protective from metabolic dysfunction. OBJECTIVE: We studied associations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) with incident diabetes, metabolic syndrome (MetS), and MetS components. METHODS: A total of 2899 participants with baseline (2003-2007) and follow-up (2013-2016) examinations and baseline NT-proBNP measurement in the REasons for Geographic And Racial Differences in Stroke study. Logistic regression models were fitted to incident MetS, MetS components, and diabetes; covariates included demographics, risk and laboratory factors. Incident diabetes was defined as fasting glucose ≥126 mg/dL, random glucose ≥200 mg/dL, or use of insulin or hypoglycemic drugs at follow-up but not baseline. Incident MetS was defined as participants with ≥3 harmonized criteria at follow-up and <3 at baseline. RESULTS: A total of 310 participants (2364 at risk) developed diabetes and 361 (2059 at risk) developed MetS over a mean 9.4 years of follow-up. NT-proBNP was inversely associated with odds of incident diabetes (fully adjusted OR per SD higher log NT-proBNP 0.80, 95% CI 0.69-0.93) and MetS in the highest vs lowest quartile only (fully adjusted OR 0.59, 95% CI 0.37-0.92); the linear association with incident MetS was not statistically significant. NT-proBNP was inversely associated with incident dysglycemia in all models (fully adjusted OR per SD log NT-proBNP 0.65, 95% CI 0.53-0.79), but not with other MetS components. Effect modification by sex, race, age, or body mass index was not observed. CONCLUSION: NT-proBNP was inversely associated with odds of diabetes, MetS, and the MetS dysglycemia component. The metabolic implications of B-type natriuretic peptides appear important for glycemic homeostasis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Nicoli CD, Long DL, Plante TB, et al. N-terminal Pro-B-Type Natriuretic Peptide and Risk for Diabetes Mellitus and Metabolic Syndrome. J Clin Endocrinol Metab. 2025. PMID: 38703102. doi:10.1210/clinem/dgae301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。